Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Interferon Alfa-2b and Interleukin-2 in Metastatic Renal Cell Carcinoma and Melanoma
NCT00003091Phase 2Completed
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Jan 1996
- Primary completion
- Jan 2000
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon alfa-2b, aldesleukin in metastatic renal cell carcinoma (mRCC), melanoma, sponsored by Hoag Memorial Hospital Presbyterian. Started Jan 1996; status: completed.
02
Drugs
interferon alfa-2baldesleukin
03
Conditions
metastatic renal cell carcinoma (mRCC)melanoma
Beyond the preview
Go deeper on NCT00003091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003091.